Eurocine Vaccines expects clinical results June/July 2017

Eurocine Vaccines expects results from the ongoing immunological analyses in June/July 2017. The samples presently being analyzed were collected during the clinical study on the nasal influenza vaccine candidate Immunose™ FLU, conducted in the current influenza season, 2016/2017.

“I am pleased that the progress of the immunological analyses has been somewhat faster than expected”, said CSO Dr. Anna-Karin Maltais.”

CEO of Eurocine Vaccines AB 

+46 70 634 0171

Eurocine Vaccines is a publicly listed company, using its clinically validated and patented technology Endocine™ initially to develop a nasal influenza vaccine for children. Within the market for influenza vaccines, children is the fastest growing segment. This is due to the recommendation by the WHO to vaccinate children against influenza. The company´s main project, the nasal quadrivalent influenza vaccine candidate Immunose™ FLU, is in clinical phase I/II development during the influenza season 2016/2017. Good safety has been reported and a report on the immune responses from the study is expected June/July 2017.

The company plans to license the product to partners for further development and commercialization.

Eurocine Vaccines, EUCI, is traded at Aktietorget, XSAT.

About Us

Eurocine Vaccines is a publicly listed, clinical-stage company developing nasal vaccines that meet important medical needs. The vaccines are developed up to proof of concept (clinical phase I/II) and licensed to partners for further development and commercialization. The company's proprietary vaccine adjuvant technologies, which are a key element of the nasal vaccines, are also offered to license partners for development in various indications. Present focus is on partnering the nasal influenza vaccine program, Immunose™ FLU, which has shown proof of concept in a clinical study, and on preclinical development of a nasal vaccine against bacterial pneumonia.


Documents & Links